Indrayani Biotech Reports Q2FY26 Results with Mixed Performance and Board Changes

Indrayani Biotech Limited submitted its Q2FY26 financial results on December 11, following board approval and audit committee recommendations. The company demonstrated mixed performance with consolidated revenue growth offset by standalone revenue decline, while implementing significant board governance changes.

Q2FY26 Financial Performance

The company's consolidated operations showed robust growth with revenue from operations reaching ₹3,594.85 lakhs compared to ₹3,081.31 lakhs in the corresponding quarter of the previous year. However, profitability metrics presented a contrasting picture:

Consolidated Metrics	Q2 Current Year	Q2 Previous Year	Growth
Revenue from Operations	₹3,594.85 lakhs	₹3,081.31 lakhs	16.66%
Total Income	₹3,774.98 lakhs	₹3,111.44 lakhs	21.33%
Net Profit After Tax	₹91.21 lakhs	₹121.69 lakhs	-25.04%
Basic EPS	₹0.09	₹0.13	-30.77%

For the half-year period ended September 30, consolidated total income reached ₹6,790.97 lakhs compared to ₹6,268.65 lakhs in the corresponding period.

Standalone Results Analysis

The standalone financial performance revealed significant operational changes with revenue decline but improved profitability margins:

Standalone Parameters	Q2 Current Year	Q2 Previous Year	Change
Revenue from Operations	₹593.13 lakhs	₹950.69 lakhs	-37.60%
Net Profit After Tax	₹46.83 lakhs	₹9.89 lakhs	373.51%
Basic EPS	₹0.10	₹0.02	400.00%

Board Governance Changes

The board meeting on December 11 approved several governance restructuring measures. Ms. Lakshmiprabha Kasiraman (DIN: 02885912) resigned from her position as Non-executive and Non-Independent Director effective November 13, citing personal commitments as the reason for her departure.

Board Changes	Details
Resigned Director	Ms. Lakshmiprabha Kasiraman (DIN: 02885912)
Resignation Date	November 13, 2025
Reason	Personal commitments
Position	Non-executive and Non-Independent Director

Following the resignation, the company reconstituted key committees with Dr. Bokara Nagarajan Padmaja Priyadarshini chairing the Nomination & Remuneration Committee, while Mr. Nangavaram Mahadevan Ranganathan leads the Stakeholders Relationship Committee.

Regulatory Compliance and Audit

The financial results received unmodified opinions from statutory auditors Venkatesh & Co, Chartered Accountants. The consolidated results encompass financial information from 7 subsidiaries and 2 step-down subsidiaries, with total revenues of ₹5,333.14 lakhs and total comprehensive profit of ₹47.26 lakhs for the subsidiaries during the period.

Compliance Details	Information
Auditor	Venkatesh & Co, Chartered Accountants
Audit Opinion	Unmodified
Subsidiaries Included	7 subsidiaries, 2 step-down subsidiaries
Total Assets	₹27,445.71 lakhs
Equity Base	₹10,381.70 lakhs

The board acknowledged previous compliance issues, including a fine of ₹16,520.00 for delayed appointment of a qualified company secretary as compliance officer, which has since been resolved with the appointment and payment of prescribed penalties.

Financial Position

As of September 30, the consolidated balance sheet reflects total assets of ₹27,445.71 lakhs with an equity base of ₹10,381.70 lakhs. The company maintains operations across diversified business segments through its subsidiary network, demonstrating operational resilience despite mixed quarterly performance metrics.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.86%	-11.87%	-19.35%	-14.35%	-67.21%	+51.15%

Indrayani Biotech Limited, a Chennai-based company, has taken a significant step towards strengthening its capital structure. The company announced that it has received in-principle approval from BSE Limited for a proposed rights issue of partly paid-up equity shares.

Key Details of the Approval

Detail	Information
Approval Date	September 19, 2025
Reference Number	LOD/RIGHT/TT/FIP/920/2025-26
Approving Authority	BSE Limited
Type of Issue	Rights Issue of Partly Paid-up Equity Shares

Company's Disclosure

The company made this announcement through a regulatory filing signed by Swaminathan G, the Whole-time Director of Indrayani Biotech Limited. The approval grants BSE's consent for the proposed rights issue under the Securities and Exchange Board of India (SEBI) listing regulations.

Additional Information

According to the LODR (Listing Obligations and Disclosure Requirements) data:

The company officially intimated the BSE about the in-principle approval on September 20, 2025.
The approval falls under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
Indrayani Biotech Limited is listed on the BSE with the scrip code 526445.

About Indrayani Biotech Limited

Indrayani Biotech Limited is headquartered at Block 1, 33, SIDCO Electronic Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai 600032. The company's Corporate Identification Number (CIN) is L40100TN1992PLC129301.

This development marks a crucial step for Indrayani Biotech as it moves forward with its capital raising plans. The rights issue, once completed, could provide the company with additional funds for its business operations and growth strategies. Shareholders and potential investors are advised to keep an eye on further announcements regarding the details of the rights issue, including the issue price, rights entitlement ratio, and the timeline for subscription.